Nov 25,2024

Australia Diabetes Market Forecasts and Company Analysis 2024-2032, Novo Nordisk, Eli Lilly, Roche, Abbott Laboratories, Insuletn, Dexcom, Medtronic, Ypsomed

The Australian diabetes devices market is projected to grow from US$ 579.4 million in 2023 to US$ 1.11 billion by 2032, driven by a CAGR of 7.55% from 2024 to 2032. The market growth is fueled by rising obesity rates, increased use of insulin delivery devices, higher diabetes prevalence, and technological advancements. With approximately 1.9 million people affected by diabetes in Australia, including a significant number of undiagnosed cases, the demand for diabetes management devices is expanding. The introduction of new, advanced products in diabetes treatment and monitoring systems, along with improved technology, is expected to further propel market growth.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Nov 25,2024

Abbott announces First Step Toward its Software-Guided Balloon-Expandable Tavi System to Treat Aortic Stenosis

Abbott has announced the first patient procedures using its investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating symptomatic severe aortic stenosis. This system is the first step towards Abbott's AI-guided TAVI platform, aimed at enhancing procedure precision and ease of use. The new system addresses the growing demand for minimally invasive treatments, especially for patients who are at high risk for open-heart surgery. Abbott's goal is to offer a broader range of TAVI options, integrating AI to improve patient outcomes and support healthcare providers with innovative tools. The first procedures were successfully conducted in Uzbekistan.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Nov 22,2024

Diabetes Injection Pens Business Analysis Report 2024-2030: Surge in Self-Monitoring Devices, Growth in Reusable Pens, mHealth for Dosage Tracking Fueling Expansion

The global market for diabetes injection pens is projected to grow from $8.5 billion in 2023 to $12.5 billion by 2030, driven by the rising prevalence of diabetes, technological advancements, and the increasing demand for patient-friendly, portable solutions. Key factors fueling this growth include the development of smart insulin pens with Bluetooth connectivity, reusable pens for cost-effectiveness, and innovations in needle design that improve comfort. As diabetes cases rise due to lifestyle factors, injection pens are becoming the preferred choice for managing the condition, particularly due to their ease of use, precise dosage control, and convenience. Expanding healthcare access, especially in emerging markets, is further supporting this trend.

View Analyst & Ambassador Comments
Go to original news
Nov 19,2024

Oviva Welcomes Healthcare Leader Michelle Carnahan As New Board Member

Oviva, the leading virtual care provider for weight-related conditions in Europe, announces the appointment of Michelle Carnahan, President of Thirty Madison, to its Board of Directors. Michelle Carnahan is a seasoned visionary leader in healthcare, known for driving innovation and growth across digital healthcare startups and Fortune 500 companies. “Michelle’s proven success in transforming healthcare businesses, including her extensive experience in the pharmaceutical sector, will be invaluable as we shape Oviva’s future," said Kai Eberhardt, CEO and Co-Founder of Oviva.

View Analyst & Ambassador Comments
Go to original news
Nov 20,2024

Optimal blood sugar control thanks to the Bluetooth® function

The Beurer GL 60 blood glucose meter offers precise and easy blood sugar monitoring, suitable for gestational diabetes. It requires only a small blood sample and features ketone and glucose warnings. The device syncs with the beurer HealthManager Pro app for real-time data tracking and analysis, supporting comprehensive health management. With a backlit display, large test strips, and multi-language support, it is designed for convenient daily use and certified as a medical device meeting European standards.

PRODUCT

#bgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 20,2024 TOP STORY

Medtronic receives FDA clearance for new InPen™ app, paving the way for its Smart MDI system launch with Simplera™ CGM

Medtronic has received FDA clearance for its new InPen™ app with missed meal dose detection, marking the launch of its Smart MDI (Multiple Daily Injection) system. This system integrates the InPen™ smart insulin pen with the Simplera™ CGM, Medtronic's first disposable, all-in-one continuous glucose monitor. The system provides real-time, personalized dosing recommendations, addressing missed or inaccurate insulin doses—a common challenge for diabetes patients on MDI therapy. It aims to simplify diabetes management, improve glucose control, and reduce health risks. A limited release will begin with existing customers, followed by a broader rollout.

REGULATORY FDA

#mobile app

#insulin pen

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 20,2024 TOP STORY

Insulet Announces Omnipod® 5 System is Now Compatible with Abbott’s FreeStyle Libre 2 Plus Sensor in the U.S.

Insulet Corporation has announced that its Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott's FreeStyle Libre 2 Plus CGM in the U.S., making Omnipod 5 the most connected tubeless AID system available. The integration allows individuals with diabetes to use their preferred CGM while benefiting from Omnipod 5’s tubeless, automated insulin delivery. Omnipod 5 adjusts insulin every five minutes using its SmartAdjust™ technology, eliminating the need for multiple daily injections (MDI) and providing enhanced glucose control. This user-friendly, waterproof system is suitable for both type 1 and type 2 diabetes, offering discreet, wearable management and continuous communication with the CGM to correct for high glucose levels and protect against lows.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 19,2024 TOP STORY

Health2Sync Partners with Singapore Health Promotion Board and Abbott to Launch Innovative DigiCoach Program Tackling Pre-diabetes and Obesity

Health2Sync has partnered with Singapore's Health Promotion Board (HPB) and Abbott to launch DigiCoach, an automated engagement program aimed at preventing diabetes in individuals with pre-diabetes or high BMI. Leveraging Abbott's Continuous Glucose Monitor (CGM) and the Health2Sync app, DigiCoach provides real-time glucose insights, personalized coaching, and lifestyle feedback. Participants use CGMs and Fitbits to track glucose patterns and exercise, receiving tailored recommendations for improved health. The 10-month pilot program, launched in July 2024, showcases public-private collaboration in addressing public health challenges and aims to create scalable solutions for better global health management.

COLLABORATION PARTNERSHIP

#cgm

#coaching

#product & service

View Analyst & Ambassador Comments
Go to original news
Nov 19,2024 TOP STORY

Dexcom and ŌURA Announce Strategic Partnership

DexCom and ŌURA have announced a strategic partnership to integrate Dexcom's glucose biosensing technology with ŌURA's smart ring data, providing users with a comprehensive view of metabolic health. The collaboration will combine glucose monitoring with biometrics such as sleep, stress, heart health, and activity, empowering users to better understand the links between lifestyle choices and glucose levels. Dexcom has also invested $75 million in ŌURA’s Series D funding. The partnership aims to launch its first app integration in early 2025, enabling personalized insights and promoting proactive health management.

COLLABORATION PARTNERSHIP

#cgm

#product & service

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 19,2024

Abbott Unveils New Recommendations and Partnerships to Improve Diversity in Clinical Trials

Abbott has announced the third year of its Diversity in Clinical Trials initiative, publishing a report titled Advancing Diversity in Clinical Trials, which offers strategies to make clinical research more inclusive. The company highlights key barriers to trial participation, such as trust, access, and language, and provides recommendations for overcoming them. Abbott has launched new partnerships and a dedicated website to educate physicians and patients, as well as a pilot program to incorporate diverse patient feedback into trial design. These efforts aim to improve access to clinical trials for underrepresented groups and drive medical innovation.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES